Blog / Nanomedicines

Nanomedicines

Insights and perspectives from our team on industry trends and scientific advances.

Quality by design for next-generation nanomedicine: Ardena co-authors NanoDDS 2025 review

Nanomedicine has progressed far beyond its early role as an experimental drug-carrier toolbox. That is the premise of “Nanomedicine beyond carriers: devices, cells & living therapeutics”, a collaborative review published in Biomedical Microdevices on 8 September 2026, in the Special Issue dedicated to the NanoDDS 2025 conference. Silvie Meeuwissen, Director Process R&D and Manufacturing, Nanomedicines […]

Read more October 21, 2026
LNP Manufacturing Market: Growth, CDMO Trends and What Developers Need to Know

LNP Manufacturing Market: Growth, CDMO Trends and What Developers Need to Know

LNP manufacturing has become one of the fastest-growing areas in modern pharmaceutical development. Lipid nanoparticles (LNPs) have moved from a niche formulation approach to one of the most validated platforms for delivering complex therapeutic payloads, and demand for specialized development and manufacturing partners has grown alongside them. According to market research firm InsightAce Analytic, the […]

Read more August 20, 2026
Advancing Nanomedicine: What to Expect at the ‘Nanomedicine & Bioconjugation Symposium 2026’

Advancing Nanomedicine: What to Expect at the ‘Nanomedicine & Bioconjugation Symposium 2026’

In the complex world of nanomedicine, staying ahead of analytical challenges is a core focus of our work at Ardena. We are looking forward to taking this conversation further at our upcoming ‘Nanomedicine & Bioconjugation Symposium 2026’ this September. As an organization, our guiding principle is “We Know Nano™,” reflecting our deep-rooted expertise in navigating […]

Read more July 8, 2026
The Analytical Blind Spot: Resolving the Matrix Complexities of Nanomedicine Payloads

The Analytical Blind Spot: Resolving the Matrix Complexities of Nanomedicine Payloads

Developing complex nanomedicines like lipid nanoparticles (LNPs) and polymeric micelles introduces unique challenges for traditional bioanalytical validation. In conventional small-molecule formulations, quantifying drug concentrations is a straightforward process of extraction and chromatographic resolution. However, within a nanomedicine matrix, the active pharmaceutical ingredient (API) exists in a dynamic equilibrium, partitioned between an encapsulated core and an […]

Read more May 24, 2026
Expanding the Therapeutic Horizon: Shifting from Transient Vaccination to Genomic Medicine

Expanding the Therapeutic Horizon: Shifting from Transient Vaccination to Genomic Medicine

The global validation of mRNA technology during the COVID-19 pandemic established lipid-encapsulated nucleic acids as a viable class of modern biopharmaceuticals. However, the molecular requirements for prophylactic vaccines represent only a fraction of the broader capabilities of mRNA therapeutics. In a vaccine application, the target payload simply needs to induce a brief, localized immune response […]

Read more May 24, 2026
The Sterilization Paradox: Balancing Product Sterility with Nanoparticle Integrity

The Sterilization Paradox: Balancing Product Sterility with Nanoparticle Integrity

The successful transition of a complex nanomedicine from a laboratory process to a scalable, cGMP-compliant drug product requires overcoming severe fluid-dynamics and engineering constraints during downstream processing. While establishing absolute sterility is a non-negotiable mandate for all parenteral injectables, the physical properties of nano-sized drug products complicate standard industry protocols. Traditional sterilization methods, such as […]

Read more May 24, 2026
Navigating the Regulatory Path for Nano-sized Drug Products

Navigating the Regulatory Path for Nano-sized Drug Products

Translating a nanomedicine candidate from successful preclinical proof-of-concept into a compliant clinical drug product requires early alignment with evolving regulatory expectations. Unlike conventional small molecules, nano-sized drug products present distinct biological and structural complexity. Their safety and therapeutic performance are governed not just by chemical composition, but by the physical architecture of the structured particle […]

Read more May 24, 2026
Overcoming Nucleic Acid Delivery Barriers: The Critical Need for Custom Lipids in Targeted Therapeutics

Overcoming Nucleic Acid Delivery Barriers: The Critical Need for Custom Lipids in Targeted Therapeutics

The therapeutic potential of genetic medicine hinges entirely on the efficiency of intracellular delivery. While mRNA therapeutics have revolutionized fields ranging from oncology immunotherapy to rare disease interventions, their clinical translation is restricted by the biological fragility of nucleic acids. Unprotected mRNA molecules face immediate enzymatic degradation by extracellular RNases and possess a highly negative […]

Read more May 24, 2026